Belite Bio Inc is a clinical stage biopharmaceutical company that develops novel therapies for retinal degenerative eye diseases, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1 (STGD1). The company's lead product candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxins in the eye that cause these diseases.
Operating in the healthcare sector, Belite Bio's pipeline of therapies targets unmet medical needs in retinal degenerative eye diseases, which affect millions of people worldwide.
Stay up to date on the share price of BLTE by adding it to your eToro watchlist.